169206-66-0

Basic information

• Product Name: tert-butyl 4-(2-methoxy-2-oxoethyl)-4-(nitromethyl)piperidine-1-carboxylate
• Synonyms: tert-butyl 4-(2-methoxy-2-oxoethyl)-4-(nitromethyl)piperidine-1-carboxylate;4-Piperidineacetic acid, 1-[(1,1-diMethylethoxy)carbonyl]-4-(nitroMethyl)-, Methyl ester
• CAS NO: 169206-66-0
• Molecular Formula: C₁₄H₂₄N₂O₆
• Molecular Weight: 316.35016
• Mol File: 169206-66-0.mol

Chemical Properties

• Boiling Point: 411.3±10.0 °C(Predicted)
• Appearance: /
• Density: 1.152±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 8.23±0.20(Predicted)
• CAS DataBase Reference: tert-butyl 4-(2-methoxy-2-oxoethyl)-4-(nitromethyl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(2-methoxy-2-oxoethyl)-4-(nitromethyl)piperidine-1-carboxylate(169206-66-0)
• EPA Substance Registry System: tert-butyl 4-(2-methoxy-2-oxoethyl)-4-(nitromethyl)piperidine-1-carboxylate(169206-66-0)

Safety Data

• Hazardous Substances Data: 169206-66-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl 4-(2-methoxy-2-oxoethyl)-4-(nitromethyl)piperidine-1-carboxylate is used as an intermediate in organic synthesis for the production of pharmaceuticals. Its complex structure and reactivity contribute to the development of new drug compounds with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, tert-butyl 4-(2-methoxy-2-oxoethyl)-4-(nitromethyl)piperidine-1-carboxylate is employed as a key component in the synthesis of various agrochemicals. Its unique properties allow for the creation of effective products for agricultural use.
Used in Chemical Research and Development:
Tert-butyl 4-(2-methoxy-2-oxoethyl)-4-(nitromethyl)piperidine-1-carboxylate serves as a valuable tool in chemical research and development due to its potential biological activity and unique structural features. It aids scientists in exploring new avenues for compound development and understanding the underlying mechanisms of action.

Upstream product

• 75-52-5 nitromethane 
• 169206-65-9 1-tert-butoxycarbonyl-4-[(methoxycarbonyl)methylene]piperidine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 685544-35-8 4-(3-oxo-2,8-diazaspiro[4.5]decan-2-yl)benzonitrile 
• 1254733-80-6 tert-butyl 2-(4-(methoxycarbonyl)phenyl)-3-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate 

Relevant articles and documents

Design, synthesis and biological evaluation of novel spiro-pentacylamides as acetyl-CoA carboxylase inhibitors

Acetyl-CoA carboxylase (ACC) catalyzes the rate-determining step in de novo lipogenesis and plays an important role in the regulation of fatty acid oxidation. Therefore, ACC inhibition offers a promising option for intervention in nonalcoholic fatty liver disease (NAFLD), type 2 diabetes (T2DM) and cancer. In this paper, a series of spiropentacylamide derivatives were synthesized and evaluated for their ACC1/2 inhibitory activities and anti-proliferation effects on A549, H1975, HCT116, SW620 and Caco-2 cell lines in vitro. Compound 6o displayed potent ACC1/2 inhibitory activity (ACC1 IC50 = 0.527 μM, ACC2 IC50 = 0.397 μM) and the most potent anti-proliferation activities against A549, H1975, HCT116, SW620 and Caco-2 cell lines, with IC50 values of 1.92 μM, 0.38 μM, 1.22 μM, 2.05 μM and 5.42 μM respectively. Further molecular docking studies revealed that compound 6o maintained hydrogen bonds between the two carbonyls and protein backbone NHs (Glu-B2026 and Gly-B1958). These results indicate that compound 6o is a promising ACC1/2 inhibitor for the potent treatment of cancer.

MUSCARINIC RECEPTOR AGONISTS

This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where m, p, q, W, Z, Y, X1, X2, R1, R2 R3 and R4 are as defined herein.

Design, syntheses, and SAR of 2,8-diazaspiro[4.5]decanones as T-type calcium channel antagonists

It was hypothesized that an appropriately substituted 2,8-diazaspiro[4.5] decan-1-one could effectively approximate a 5-feature T-type pharmacophore model published in the literature. Compounds were designed and synthesized to test our hypothesis and were found to be potent T-type calcium channel inhibitors with modest selectivity over L-type calcium channels. The synthesis and SAR of the series is described.

Rifamycin derivatives

Novel rifamycin derivatives of formula I (both hydroquinone and corresponding quinone (C1-C4) forms): or their salts, hydrates or prodrugs thereof, wherein: a preferred R comprises hydrogen, acetyl; L is a linker, a preferred linker group elements selected from any combination of 1 to 5 groups shown FIG. 1, provided L is not wherein R1 is H, methyl or alkyl. The inventive compounds exhibit valuable antibiotic properties. Formulations having these compounds can be used in the control or prevention of infectious diseases in mammals, both humans and non-humans. In particular, the compounds exhibit a pronounced antibacterial activity, even against multiresistant strains of microbes.

New Spiropiperidines as Potent and Selective Non-Peptide Tachykinin NK2 Receptor Antagonists

The synthesis of a series of 2-(5-fluoro-1H-indol-3-yl)ethyl spiropiperidines is described together with their tachykinin NK2 receptor affinities measured in a rat colon binding assay.Equivalent NK2 receptor binding affinity was observed for the spirooxalidinone 3-benzyl-8--1-oxa-3,8-diazaspirodecan-2-one (3a), the imidazolidinone 3-benzyl-8--1,3,8-triazaspirodecan-2-one (3s), and the pyrrolidinone 2-benzyl-8--2,8-diazaspirodecan-3-one (3t).Substitution in the phenyl ring of compound 3a produced no significant enhancement in NK2 binding affinity.Replacement of the phenyl ring in 3a with other aromatic rings resulted in a significant loss in binding affinity.Compound 3a was shown to be a potent NK2 receptor antagonist in guinea pig trachea where it also demonstrated 1000-fold selectivity for NK2 receptors over NK1.In the anesthesized guinea pig, compound 3a administered by the intravenous or oral route displayed potent and long-lasting antagonist activity against NK2 receptor agonist induced bronchoconstriction.